Nascent Biotech, Inc. (NBIO)
USD 0.01
(44.44%)
USD 0.01
(44.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 2.22 Million USD | 4.19% |
| 2023 | 2.14 Million USD | 46.89% |
| 2022 | 1.45 Million USD | -32.24% |
| 2021 | 2.15 Million USD | -37.62% |
| 2020 | 3.44 Million USD | 151.82% |
| 2019 | 1.36 Million USD | -38.38% |
| 2018 | 2.22 Million USD | 41.28% |
| 2017 | 1.57 Million USD | -71.12% |
| 2016 | 5.44 Million USD | 155.82% |
| 2015 | 2.12 Million USD | 11.66% |
| 2014 | 1.9 Million USD | 182.65% |
| 2013 | 674.31 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 516.02 Thousand USD | 41.6% |
| 2024 Q3 | 364.42 Thousand USD | -56.48% |
| 2024 Q1 | 511.97 Thousand USD | -2.35% |
| 2024 FY | 2.22 Million USD | 4.19% |
| 2024 Q2 | 837.45 Thousand USD | 63.57% |
| 2023 Q2 | 521.23 Thousand USD | -15.89% |
| 2023 Q1 | 619.67 Thousand USD | 49.33% |
| 2023 FY | 2.14 Million USD | 46.89% |
| 2023 Q4 | 524.29 Thousand USD | 10.37% |
| 2023 Q3 | 475.02 Thousand USD | -8.86% |
| 2022 Q2 | 230.23 Thousand USD | -48.01% |
| 2022 FY | 1.45 Million USD | -32.24% |
| 2022 Q1 | 442.8 Thousand USD | -8.34% |
| 2022 Q3 | 369.02 Thousand USD | 60.28% |
| 2022 Q4 | 414.98 Thousand USD | 12.45% |
| 2021 Q2 | 561 Thousand USD | 1.75% |
| 2021 Q1 | 551.34 Thousand USD | -77.48% |
| 2021 FY | 2.15 Million USD | -37.62% |
| 2021 Q4 | 483.07 Thousand USD | -12.95% |
| 2021 Q3 | 554.93 Thousand USD | -1.08% |
| 2020 FY | 3.44 Million USD | 151.82% |
| 2020 Q3 | 368.32 Thousand USD | 12.46% |
| 2020 Q2 | 327.52 Thousand USD | 19.65% |
| 2020 Q1 | 273.74 Thousand USD | -18.2% |
| 2020 Q4 | 2.44 Million USD | 564.58% |
| 2019 Q1 | 439.72 Thousand USD | -45.12% |
| 2019 Q4 | 334.63 Thousand USD | 30.43% |
| 2019 Q3 | 256.57 Thousand USD | -24.09% |
| 2019 FY | 1.36 Million USD | -38.38% |
| 2019 Q2 | 338.01 Thousand USD | -23.13% |
| 2018 Q1 | 298.54 Thousand USD | -35.71% |
| 2018 Q2 | 558.22 Thousand USD | 86.98% |
| 2018 Q3 | 563.67 Thousand USD | 0.98% |
| 2018 FY | 2.22 Million USD | 41.28% |
| 2018 Q4 | 801.31 Thousand USD | 42.16% |
| 2017 Q3 | 569.75 Thousand USD | -14.25% |
| 2017 FY | 1.57 Million USD | -71.12% |
| 2017 Q4 | 464.38 Thousand USD | -18.49% |
| 2017 Q2 | 664.43 Thousand USD | 422.96% |
| 2017 Q1 | 127.05 Thousand USD | -78.8% |
| 2016 Q1 | 772.67 Thousand USD | -15.45% |
| 2016 Q4 | 599.35 Thousand USD | 126.92% |
| 2016 Q3 | 264.12 Thousand USD | -88.17% |
| 2016 FY | 5.44 Million USD | 155.82% |
| 2016 Q2 | 2.23 Million USD | 188.88% |
| 2015 Q2 | 328.08 Thousand USD | 41.63% |
| 2015 FY | 2.12 Million USD | 11.66% |
| 2015 Q1 | 231.64 Thousand USD | -37.62% |
| 2015 Q3 | 654.61 Thousand USD | 99.52% |
| 2015 Q4 | 913.83 Thousand USD | 39.6% |
| 2014 Q3 | 1.39 Million USD | 1872.53% |
| 2014 Q2 | 70.97 Thousand USD | 5.45% |
| 2014 FY | 1.9 Million USD | 182.65% |
| 2014 Q4 | 371.36 Thousand USD | -73.47% |
| 2014 Q1 | 67.3 Thousand USD | 0.0% |
| 2013 FY | 674.31 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -66.978% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 55.774% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 92.455% |
| Rebus Holdings, Inc. | 664 Thousand USD | -235.825% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 94.015% |
| Qrons Inc. | 643.67 Thousand USD | -246.428% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -472.401% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.118% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -436.701% |
| Skye Bioscience, Inc. | 13.54 Million USD | 83.54% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.431% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 54.658% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -751.99% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.396% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 23.536% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -48.471% |
| Mesoblast Limited | 5.9 Million USD | 62.218% |
| Marizyme, Inc. | 19.23 Million USD | 88.41% |
| Genus plc | 147.7 Million USD | 98.49% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 74.601% |
| Pharming Group N.V. | 225.49 Million USD | 99.011% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -8.843% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -66.217% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 73.26% |
| ContraFect Corporation | 56.88 Million USD | 96.08% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 49.421% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -50.795% |
| IMV Inc. | 37.7 Million USD | 94.087% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 20.086% |
| MultiCell Technologies, Inc. | 567.42 USD | -392885.619% |
| ONE Bio Corp. | 6.44 Million USD | 65.395% |
| Accustem Sciences Inc. | 3.74 Million USD | 40.48% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.405% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -319.18% |
| Q BioMed Inc. | 3.43 Million USD | 35.114% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.978% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 15.134% |
| Biomind Labs Inc. | 994.18 Thousand USD | -124.293% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.755% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -26.721% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 66.807% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -19.605% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9019.516% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 86.072% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -21.513% |
| GB Sciences, Inc. | 1.42 Million USD | -56.977% |
| Alpha Cognition Inc. | 9.7 Million USD | 77.025% |
| HST Global, Inc. | 140.9 Thousand USD | -1482.518% |
| CSL Limited | 3.44 Billion USD | 99.935% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -98.227% |
| Halberd Corporation | 74.84 Thousand USD | -2879.449% |
| Enzolytics Inc. | 2.17 Million USD | -2.311% |
| Agentix Corp. | 1.37 Million USD | -62.557% |
| Resverlogix Corp. | 12.71 Million USD | 82.458% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 38.919% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.855% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -113.59% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 7.279% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -41.189% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 34.511% |
| AVAX Technologies, Inc. | 7.31 Million USD | 69.497% |
| Zenith Capital Corp. | 8.94 Million USD | 75.066% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.73% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -12699.948% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 9.182% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1200.153% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -16.085% |
| Kadimastem Ltd | 2.41 Million USD | 7.478% |
| Helix BioMedix, Inc. | 1.97 Million USD | -13.075% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 79.48% |
| BioStem Technologies, Inc. | 22.97 Million USD | 90.294% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1128.685% |
| LadRx Corporation | 3.81 Million USD | 41.5% |
| Cell Source, Inc. | 4.32 Million USD | 48.446% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -141.457% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -141.457% |
| NovAccess Global Inc. | 2.46 Million USD | 9.603% |
| Affymax, Inc. | 39.38 Million USD | 94.338% |
| Itoco Inc. | 919.14 Thousand USD | -142.604% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 47.389% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -99.274% |
| Mobile Lads Corp. | 554.54 Thousand USD | -302.109% |
| CytoDyn Inc. | 18.05 Million USD | 87.652% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -8759.625% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -913.222% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -57.057% |
| SYBLEU INC | 160.87 Thousand USD | -1286.086% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -22.769% |
| International Stem Cell Corporation | 5.27 Million USD | 57.695% |
| Bioxytran, Inc. | 3.82 Million USD | 41.628% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4135.931% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -10861.407% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.851% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -37.817% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -203.041% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 28.323% |
| Neutra Corp. | 243.82 Thousand USD | -814.556% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 87.226% |
| PureTech Health plc | 144.59 Million USD | 98.458% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 89.117% |
| IXICO plc | 4.7 Million USD | 52.626% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 74.652% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.106% |
| CSL Limited | 3.89 Billion USD | 99.943% |
| Cellectis S.A. | 97.32 Million USD | 97.709% |